论文部分内容阅读
目的:探讨过氧化物酶体增殖激活物受体β(PPARβ)的表达及其与上皮性卵巢癌临床病理特征间的关系。方法:用免疫组织化学染色和半定量RT-PCR法检测PPARβ在正常卵巢组织和卵巢癌组织的表达。结果:PPARβ在上皮性卵巢癌和非癌组织均有表达,PPARβ的表达定位于细胞质中,在正常卵巢、卵巢交界性肿瘤、浆液性囊腺癌中PPARβ表达阳性率分别为20%、50%及89·1%。在浆液性囊腺癌中表达明显高于交界性肿瘤和正常卵巢组织(P<0·05),且与临床分期、组织学分级和淋巴结转移有关(P<0·05)。结论:PPARβ表达水平增高可能与卵巢上皮癌的分化转移有关。
Objective: To investigate the expression of peroxisome proliferator-activated receptor β (PPARβ) and its relationship with clinicopathological features of epithelial ovarian cancer. Methods: Immunohistochemical staining and semi-quantitative RT-PCR were used to detect the expression of PPARβ in normal ovarian tissue and ovarian cancer. Results: The expression of PPARβ was localized in epithelial ovarian and non-cancerous tissues, and the expression of PPARβ was localized in the cytoplasm. The positive rates of PPARβ in normal ovarian, borderline ovarian tumors and serous cystadenocarcinomas were 20% and 50% And 89.1%. The expression in serous cystadenocarcinoma was significantly higher than that in borderline tumors and normal ovarian tissues (P <0.05), and was related to clinical stage, histological grade and lymph node metastasis (P <0.05). Conclusion: The increased expression of PPARβ may be related to the differentiation and metastasis of epithelial ovarian cancer.